Companies, advocates and investors in the psychedelic field are hopeful the Trump administration will support the space after favorable sentiments by several key officials, STAT News’ Olivia Goldhill and Meghana Keshavan report, citing sources. Robert F. Kennedy Jr., the secretary of health and human services, has voiced support for psychedelics as a potential mental health treatment and Calley Means, a White House adviser, wrote that psychedelics “should be an important public policy priority for the United States”. Additionally, Casey Means, the president’s surgeon general pick, described psilocybin therapy as “one of the most meaningful experiences of life” and FDA Commissioner Marty Makary has made positive remarks on the opportunity the substances could hold for veterans. Publicly-traded companies in the space include atai Life Sciences (ATAI), Clearmind (CMND), Compass Pathways (CMPS), Cybin (CYBN), GH research (GHRS) and Mind Medicine (MNMD).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATAI: